Silk Road Medical has appointed Andrew Davis to the position of executive vice president of global pales. In this new role, Davis will assemble a sales organisation and lead the company’s commercialisation efforts for the transcarotid artery revascularisation (TCAR) procedure with the Enroute transcarotid neuroprotection system and the Enroute transcarotid stent system.
Prior to joining Silk Road Medical, Davis was the vice president of sales and marketing at Acelity’s Advanced Wound Therapy Group and previously held vice president of sales positions for Medtronic’s CoreValve, Endovascular, Peripheral and Spinal/Biologics divisions. He has over 20 years of experience in the medical device field with deep expertise in launching innovative, minimally invasive therapies that increase patient access and solve unmet clinical needs in cardiovascular diseases historically treated with invasive surgical approaches.
“Andrew is the ideal sales leader to help Silk Road redefine carotid artery revascularisation and realise its mission to beat stroke and its devastating effects on patients, families and society,” said Erica Rogers, chief executive officer. “Andrew’s deep knowledge of endovascular surgery, extensive relationships, and track record of success will be incredibly valuable to our team as we commercialise in the USA and beyond.”
“Silk Road has completely changed the way we think about treating carotid artery disease,” said Davis. “There are known and sometimes severe complications with open carotid surgery, and transfemoral carotid stenting with current technology actually increases the stroke risk. TCAR is a clinically proven game-changer, as demonstrated by the ROADSTER trial, with the clear potential to become standard of care.”
